Regeneron Pharmaceuticals (REGN) Inventory (2012 - 2026)

Regeneron Pharmaceuticals' Inventory history runs 15 years deep, the most recent figure standing at $3.1 billion for Q1 2026.

• On a quarterly basis, Inventory fell 2.78% year-over-year to $3.1 billion in Q1 2026; TTM through Mar 2026 was $3.1 billion, a 2.78% decrease from a year earlier, with the FY2025 full-year figure at $3.2 billion, up 3.68% from the prior year.
• Inventory eased to $3.1 billion in Q1 2026 per REGN's latest filing, from $3.2 billion in the prior quarter.
• Across five years, Inventory topped out at $3.3 billion in Q3 2025 and bottomed at $2.0 billion in Q1 2022.
• The 5-year median for Inventory is $2.7 billion (2024), against an average of $2.7 billion.
• Biggest YoY gain for Inventory was 23.09% in 2022; the steepest drop was 8.0% in 2022.
• Year by year, Inventory stood at $2.4 billion in 2022, then rose by 7.44% to $2.6 billion in 2023, then increased by 19.64% to $3.1 billion in 2024, then grew by 3.68% to $3.2 billion in 2025, then retreated by 3.04% to $3.1 billion in 2026.
• Per Business Quant, the three latest REGN Inventory figures stand at $3.1 billion (Q1 2026), $3.2 billion (Q4 2025), and $3.3 billion (Q3 2025).